Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The primary objective of the phase 1 trial is to identify a dose of topotecan that will be
safe to take forward into a Phase 2 trial, with no unexpected toxicities or drug-drug
interactions with standard therapy for COVID-19. The investigators hypothesise that a single
dose of low-dose Topotecan will blunt the expression of inflammatory genes in patients with
moderate COVID-19, without cytotoxic side effects.